Current Environment: Production

Medical Services

Programs & Services

Languages

  • English

Education

Medical School

Smolensk State Medical Academy

, Russia

Residency

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, PA

Fellowship

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Boston, MA

Certifications

  • American Board of Pediatrics (General)

Professional History

While a medical student in Russia, my research was focused on various aspects of clinical and molecular microbiology. After graduating from medical school, I pursued a Ph.D. in biochemistry and my research under the mentorship of Dr. G. Douglas Markham at the Fox Chase Cancer Center in Philadelphia was focused on the role of the metabolic enzyme IMP dehydrogenase in the regulation of purine and energy metabolism. Subsequently, my interest in pediatric hematology/oncology and blood development prompted me to join the laboratory of Dr. Mitchell Weiss at the Children’s Hospital of Philadelphia, where I studied the global transcriptional networks that govern hematopoietic lineage priming and specification. In 2011 I joined a Pediatric Residency program at the Children’s Hospital of Pittsburgh, which I finished in 2014, followed by fellowship training in Pediatric Hematology Oncology at the Boston Children’s/Dana-Farber Cancer and Blood Disorders Center from 2014-2017. I am looking forward to a productive academic career where I hope to combine clinical work with basic research in hematopoiesis, stem cell biology and cancer, with the ultimate goal of establishing an independent, NIH-funded laboratory.

Publications

  1. Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series. EBioMedicine. 2024 Jun; 104:105147. View Abstract

  2. FISH-Flow to quantify nascent and mature ribosomal RNA in mouse and human cells. STAR Protoc. 2023 09 15; 4(3):102463. View Abstract

  3. Construction and validation of customized genomes for human and mouse ribosomal DNA mapping. J Biol Chem. 2023 06; 299(6):104766. View Abstract

  4. Rapid-kinetics degron benchmarking reveals off-target activities and mixed agonism-antagonism of MYB inhibitors. bioRxiv. 2023 Apr 07. View Abstract

  5. Leukemia core transcriptional circuitry is a sparsely interconnected hierarchy stabilized by incoherent feed-forward loops. bioRxiv. 2023 Mar 15. View Abstract

  6. Control of ribosomal RNA synthesis by hematopoietic transcription factors. Mol Cell. 2022 10 20; 82(20):3826-3839.e9. View Abstract

  7. Transcriptional Plasticity Drives Leukemia Immune Escape. Blood Cancer Discov. 2022 09 06; 3(5):394-409. View Abstract

  8. Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. Cancer Discov. 2022 07 06; 12(7):1760-1781. View Abstract

  9. Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Cell Rep. 2022 04 26; 39(4):110752. View Abstract

  10. A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes Dev. 2022 03 01; 36(5-6):368-389. View Abstract

  11. Dynamic shifts in occupancy by TAL1 are guided by GATA factors and drive large-scale reprogramming of gene expression during hematopoiesis. Genome Res. 2014 Dec; 24(12):1945-62. View Abstract

  12. Divergent functions of hematopoietic transcription factors in lineage priming and differentiation during erythro-megakaryopoiesis. Genome Res. 2014 Dec; 24(12):1932-44. View Abstract

  13. Lineage and species-specific long noncoding RNAs during erythro-megakaryocytic development. Blood. 2014 Mar 20; 123(12):1927-37. View Abstract

  14. The calcineurin-NFAT pathway negatively regulates megakaryopoiesis. Blood. 2013 Apr 18; 121(16):3205-15. View Abstract

  15. An encyclopedia of mouse DNA elements (Mouse ENCODE). Genome Biol. 2012 Aug 13; 13(8):418. View Abstract

  16. Dynamics of the epigenetic landscape during erythroid differentiation after GATA1 restoration. Genome Res. 2011 Oct; 21(10):1659-71. View Abstract

  17. A regulatory role of the Bateman domain of IMP dehydrogenase in adenylate nucleotide biosynthesis. J Biol Chem. 2009 Mar 20; 284(12):7960-9. View Abstract

  18. Inosine 5'-monophosphate dehydrogenase. Adv Enzymol Relat Areas Mol Biol. 2009; 76:1-53. View Abstract

  19. The CBS subdomain of inosine 5'-monophosphate dehydrogenase regulates purine nucleotide turnover. Mol Microbiol. 2008 Apr; 68(2):342-59. View Abstract

  20. Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains. Antimicrob Agents Chemother. 2008 Apr; 52(4):1297-301. View Abstract

  21. Recombinant nucleases CEL I from celery and SP I from spinach for mutation detection. BMC Biotechnol. 2007 Jun 01; 7:29. View Abstract

  22. Characterization of a periplasmic S1-like nuclease coded by the Mesorhizobium loti symbiosis island. Biochem Biophys Res Commun. 2006 Apr 28; 343(1):77-84. View Abstract

  23. Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum beta-lactamase. Antimicrob Agents Chemother. 2004 Aug; 48(8):2808-15. View Abstract

  24. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother. 2003 Dec; 47(12):3724-32. View Abstract
BESbswy